Who Paid My Doc
Brendan Clark
Critical Care Medicine Lakewood, CO Medical Doctor
NPI 1265419659 CMS profile 1054759
274 Union Blvd Ste 110, Lakewood, CO 80228
General payments
$445
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Brendan Clark of Lakewood, CO is reported in the CMS Open Payments database as having received $445 across 12 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 51st percentile of Critical Care Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
5 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $108 | 4 | |
| 2024 | General | $25 | 1 | |
| 2023 | General | $242 | 3 | |
| 2022 | General | $15 | 1 | |
| 2019 | General | $55 | 3 |
Beside peers
- Brendan Clark
- Critical Care Medicine median
- Middle half of Critical Care Medicine
- National median
In program year 2025, general payments to Brendan Clark were reported at $108. Among 2,664 Critical Care Medicine profiles paid that year, the median was $189 and the middle half received between $59 and $844.
Show as a table
| Year | Brendan Clark | Critical Care Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $55 | $149 | $51–$535 | $163 |
| 2020 | $0 | $110 | $30–$325 | $114 |
| 2021 | $0 | $125 | $34–$403 | $132 |
| 2022 | $15 | $157 | $49–$582 | $149 |
| 2023 | $242 | $162 | $56–$621 | $160 |
| 2024 | $25 | $168 | $53–$634 | $164 |
| 2025 | $108 | $189 | $59–$844 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 11 drugsPart D claims
262
Drug cost
$111,768
Branded share of claims
89.3%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | Brand | 43 | $38,508 | |
| Breztri Aerosphere Budesonide/Glycopyr/Formoterol | Brand | 54 | $35,765 | |
| Dulera Mometasone/Formoterol | Brand | 27 | $12,238 | |
| Spiriva Respimat Tiotropium Bromide | Brand | 15 | $9,385 | |
| Symbicort Budesonide/Formoterol Fumarate | Brand | 25 | $6,974 | |
| Fluticasone-Salmeterol Fluticasone Propion/Salmeterol | Brand | 22 | $3,729 | |
| Arnuity Ellipta Fluticasone Furoate | Brand | 17 | $3,469 | |
| Wixela Inhub Fluticasone Propion/Salmeterol | Brand | 14 | $864 | |
| Albuterol Sulfate Hfa Albuterol Sulfate | Brand | 17 | $575 | |
| Omeprazole | Generic | 14 | $137 |
The 10 drugs with the highest cost, of 11 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 40 billing codesPaid by Medicare
$86,175
Medicare patients
291
Services billed
872
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 53% | |
| Ischemic heart disease | 47% | |
| COPD | 44% | |
| Chronic kidney disease | 41% | |
| Heart failure | 40% | |
| Depression | 38% | |
| Atrial fibrillation | 37% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
12 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Critical Care Medicine in Colorado
Peter Hountras
Critical Care Medicine · Aurora, CO
Chakradhar Kotaru
Critical Care Medicine · Greenwood Village, CO
Gregory Cosgrove
Critical Care Medicine · Denver, CO
Walter Conwell
Critical Care Medicine · Denver, CO
David Hsia
Critical Care Medicine · Denver, CO
Nitin Gupta
Critical Care Medicine · Littleton, CO
Related records
Critical Care Medicine in Colorado
Practitioners in the same specialty and state, ranked by reported value.
All Critical Care Medicine
Everyone recorded under this specialty, nationwide.
Doctors in Colorado
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.